Discussion
· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda
https://thesicktimes.org/2026/01/27/research-updates-january-27/
· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda
https://thesicktimes.org/2026/01/27/research-updates-january-27/
· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome ( #POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)
https://thesicktimes.org/2026/02/03/research-updates-february-3/
· A large study recently connected “chronic absenteeism” to pediatric #LongCOVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic
· A small mechanistic study in Brain, Behavior, & Immunity – Health found that immunoglobulin G (IgG), isolated from people with #MECFS, can destroy mitochondria in endothelial cells
· ADDRESS-LC has opened two more study sites: a new one in California and one in Connecticut
https://thesicktimes.org/2026/02/10/research-updates-february-10/
· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease
https://thesicktimes.org/2026/02/17/research-updates-february-17/
